DAWN | Day One Biopharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	13.32 - 13.71
52 Week Range	11.30 - 18.07
Beta	0.13
Implied Volatility	45.48%
IV Rank	12.46%
Day's Volume	472,902
Average Volume	1,067,911
Shares Outstanding	100,846,000
Market Cap	1,373,522,520
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-05-27

Valuation
Profitability
Growth
Health
P/E Ratio	-14.04
Forward P/E Ratio	N/A
EPS	-0.97
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	169
Country	USA
Website	DAWN

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

DAWN's peers: ABEO, ABOS, ABSI, ACHV, ACLX, AFMD, AGIO, ALDX, ALLK, ALNY, ALT, ALZN, AMLX, ANNX, ANVS, APLS, APLT, ARCT, ARGX, ARQT, ARWR, ASND, AUTL, AXSM, BBIO, BCLI, BCRX, BCTX, BHVN, BIVI, BMRN, BPMC, BTAI, CABA, CGEM, CGTX, CLDX, CMRX, CNTX, CPRX, CRBP, CRDF, CRIS, CRVS, CTXR, CUE, XFOR, INZY, MREO, TERN, ELDN, HOOK, PDSB, DMAC, DNLI, DTIL, ETNB, EYPT, FGEN, FOLD, GLSI, GLTO, GMAB, GNLX, HRTX, IDYA, IMVT, INKT, INSM, INVA, ITOS, KNSA, KURA, KZIA, LEGN, LPTX, LRMR, LXRX, LYRA, MDGL, MDXG, MDXH, MEIP, MESO, MGNX, MIRM, MIST, MNKD, MRSN, NCNA, NERV, OCUL, OMER, ONCY, OTLK, PGEN, PHAT, PRQR, PRTG, PTGX, QURE, RARE, RCKT, RCUS, RGNX, RIGL, RLAY, RNA, ROIV, RPRX, RVNC, RXRX, SAGE, SANA, SLNO, SLS, SPRB, SWTX, TCRX, TSHA, TSVT, UTHR, VCEL, VIR, VKTX, VOR, VRNA, VYGR, WVE, XBIT, XERS, YMAB, ZNTL, ZYME, MLTX, ERNA, IRON, COYA, GPCR

*Chart delayed

Analyzing fundamentals for DAWN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see DAWN Fundamentals page.

Watching at DAWN technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on DAWN Technicals page.